In addition, HER2 is an oncogenic driver for many HER2+ cancers, which makes it less likely for these cancer cells to become refractory to anti-HER2 ADCs by downregulating the antigen [83], a major mechanism of resistance to ADCs targeting antigens with no apparent biological functions for cancer cell survival. This evidence concerns the gene ERBB2 and cancer.